We are pleased to announce the winner of the 2025 Highly Cited Paper Award for Exploration of Targeted Anti-tumor Therapy. This annual award recognizes outstanding research published in the journal that has garnered significant attention and impact within the academic community.

Winning Article

Title: Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment

DOI: https://doi.org/10.37349/etat.2024.00212

Authors: Eric Jou*, Natasha Chaudhury, Fizza Nasim

The article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer

Selection Criteria

• Articles published in 2024-2025.

• Citation counts based on 2025 Web of Science (WOS) data.

Awards & Benefits

• Author Team: A monetary prize of 500 USD, a Highly Cited Paper Award certificate, and a one-time 100% APC waiver.

• Corresponding Guest Editor: A monetary prize of 200 USD.

We extend our heartfelt congratulations to all the winners and express our sincere gratitude to the authors, reviewers, and readers for their continued support of the journal. This award not only celebrates the excellence of the winning article but also reflects the journal's commitment to publishing high-quality research. 

We encourage researchers to submit their research to Exploration of Targeted Anti-tumor Therapy and join us in shaping the future of ETAT and oncology research. We look forward to recognizing more groundbreaking work in the years to come.

Highly Cited Paper Award Winners (2025).pdf